To that aim we used the commercially available selective HDAC6 inhibitor tubastatin [47] to treat ALI cells as HDAC6 is a downstream effector of AURKA (Figure 6d) and a predicted miR449 target (Supplementary Figure S5a). Here, AURKA is linked to acute respiratory distress syndrome.